Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
NYXH$0.86+0.02(+2.64%)Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026[5:05:00 PM ET]ONCO$0.38-0.04(-9.09%)Onconetix Announces Reverse Stock Split[5:03:00 PM ET]BRO$71.80-1.17(-1.60%)Brown & Brown, Inc. announces third quarter 2026 results, including total revenues of $1.7 billion, an increase of 7.4%; growth of Organic Revenue of 1.2%; growth of Organic Revenue with Contingents of 1.5%; diluted net income per share of $0.67; and Diluted Net Income Per Share - Adjusted of $1.07[5:02:02 PM ET]SRAFF$0.19+0.01(+4.22%)Sandfire Resources America Inc. Announces Strategic Review[5:01:00 PM ET]HII$281.05+6.97(+2.54%)Ingalls Shipbuilding Awards $20,000 in Community Partner Grants[5:00:00 PM ET]EGO$31.71+0.04(+0.13%)Eldorado Gold Announces Tailings Filter Presses Operational at Skouries[5:00:00 PM ET]WRN$1.74+0.05(+2.96%)Western Copper and Gold Announces Leadership Transition[5:00:00 PM ET]FFR$1.08-0.05(-4.42%)FF EAI Robotics Ecosystem (FFR) Completes Acquisition of FFAI Robotics Business, Establishing a Nasdaq-Listed Humanoid and Bionic Robotics Platform October Robot Sales Expected to Exceed 300 Units; Unveils FF OmniMind, a Unified AI Brain for All Robots FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) ("FFR" or the "Company") a U.S.-based Embodied AI robotics company, today announced at the deal closing...[5:00:00 PM ET]BANX$19.68-0.07(-0.38%)ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of September 2026[5:00:00 PM ET]GPUSF$0.17+0.00(+1.09%)Alset AI Announces Non-Brokered Private Placement Offering of a Minimum of $650,000 and a Maximum of $800,000[5:00:00 PM ET]CBK$32.00-0.22(-0.68%)Commercial Bancgroup, Inc. Announces Quarterly Cash Dividend[5:00:00 PM ET]CBK$32.00-0.22(-0.68%)Commercial Bancgroup, Inc. Announces Results for the Third Quarter 2026[5:00:00 PM ET]BRBS$4.01-0.06(-1.47%)Blue Ridge Bankshares, Inc. Announces 2026 Third Quarter Results Blue Ridge Bankshares, Inc. (the "Company") (NYSE American: BRBS), the holding company of Blue Ridge Bank, National Association ("Blue Ridge Bank" or ...[5:00:00 PM ET]IAALF$0.08+0.01(+11.40%)IBC Advanced Alloys Announces Issuance of Share-Based Compensation to Directors[5:00:00 PM ET]MVST$0.49-0.01(-1.81%)Microvast Schedules Third Quarter Earnings Call[5:00:00 PM ET]

CLLS · NASDAQ

Cellectis S.A.

$0.96 -0.02 (-2.04%)

Company overview

Cellectis S.A., a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments: Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, including acute lymphoblastic leukemia; ALLO-501 and ALLO-501A for relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for renal cell carcinoma; UCART123 for acute myeloid leukemia; and UCART22 for B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for multiple myeloma. Cellectis has strategic alliances with Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$96.7M
Employees
216
Headquarters
Paris
Website
cellectis.com
CEO
Andre Choulika
Listed
March 24, 2015
P/E
-1.40
Dividend yield
0.00%

Company financials

Revenue
$68.1M
Gross profit
$55.8M
Operating income
-$46M
EBITDA
-$51.1M
Net income
-$67.3M
EPS
-$0.68
Total assets
$289M
Total debt
$109M
Gross margin
81.89%
Net margin
-98.83%
Earnings yield
-71.26%

Revenue segmentation

By product (FY 2025)

No annual product segmentation.

By region (FY 2025)

Showing FY 2025

Price chart

0.751.652.553.454.35
CLLS 1D NASDAQ O1.00H1.02L0.96C0.98+0.01 (+0.51%)Vol13.63K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
CLLSCellectis S.A. Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS ACCESS Newswire
CLLSCellectis S.A. Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS PRNewsWire
CLLSCellectis S.A. Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS ACCESS Newswire
CLLSCellectis S.A. Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS ACCESS Newswire
CLLSCellectis S.A. Legal Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm GlobeNewswire
CLLSCellectis S.A. Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ: CLLS). PR Newswire
CLLSCellectis S.A. Legal Cellectis S.A. (CLLS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation GlobeNewswire
CLLSCellectis S.A. Legal Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz GlobeNewswire
CLLSCellectis S.A. Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS ACCESS Newswire
CLLSCellectis S.A. Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS ACCESS Newswire
CLLSCellectis S.A. Stock news Cellectis Unveils In Vivo Gene-Editing Plans for Severe Lipid Disorders MarketBeat
CLLSCellectis S.A. Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. – CLLS GlobeNewswire
CLLSCellectis S.A. Legal CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law GuruFocus
CLLSCellectis S.A. Legal CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law Business Wire
CLLSCellectis S.A. Legal CLLS INVESTOR ALERT: Investigation of Cellectis S.A. Announced by Holzer & Holzer, LLC GlobeNewsWire
CLLSCellectis S.A. Legal Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Business Wire
CLLSCellectis S.A. Legal Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Business Wire
CLLSCellectis S.A. Stock news This Nu Holdings Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday Benzinga
CLLSCellectis S.A. Stock news Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday Benzinga
CLLSCellectis S.A. Stock news This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday Benzinga
See more
FAQ

Questions about Cellectis S.A.

What does Cellectis S.A. do?
Cellectis S.A., a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments: Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, including acute lymphoblastic leukemia; ALLO-501 and ALLO-501A for relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for renal cell carcinoma; UCART123 for acute myeloid leukemia; and UCART22 for B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for multiple myeloma. Cellectis has strategic alliances with Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D.
What is CLLS's market cap?
Cellectis S.A. (CLLS) is a listed stock with a live quote. The latest market cap on this page is $96.7M.
Where is Cellectis S.A. headquartered?
Cellectis S.A. is headquartered in Paris.
How do I get CLLS news from the API?
Call GET /v1/news?tickers=CLLS. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does CLLS news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for CLLS, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the CLLS price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs